CLINICAL & PIPELINE·Drug Approval
Inhibrx Biosciences' Ozekibart BLA Acceptance Signals New Treatment Horizon for Chondrosarcoma
Inhibrx Biosciences has achieved a critical milestone with the US FDA's BLA acceptance for ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma. This development, backed by robust ChonDRAgon study data, sets a PDUFA date of April 14, 2027, and signals a significant commercial opportunity for Inhibrx in an area of high unmet medical need, impacting procurement and regulatory strategies.
90-Day Activity